scPharmaceuticals (SCPH) Soars 8.8%: Is Further Upside Left in the Stock?

scPharmaceuticals, Inc. (SCPH) shares soared 8.8% in the last trading session to close at $5.84. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 35.3% gain over the past four weeks.The sudden price rise can be attributed to growing investor optimism related to the initial sales uptake of the company's marketed product, Furoscix (furosemide injection), which is indicated for the treatment of edema in adult patients with chronic heart failure or chronic kidney disease, including nephrotic syndrome.This company is expected to post quarterly loss of $0.30 per share in its upcoming report, which represents a year-over-year change of +31.8%. Revenues are expected to be $16.4 million, up 103.7% from the year-ago quarter.Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.For scPharmaceuticals, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on SCPH going forward to see if this recent jump can turn into more strength down the road. The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>scPharmaceuticals is part of the Zacks Medical - Biomedical and Genetics industry. Celldex Therapeutics (CLDX), another stock in the same industry, closed the last trading session 2.7% lower at $23.22. CLDX has returned 11.2% in the past month.Celldex's consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.86. Compared to the company's year-ago EPS, this represents a change of -59.3%. Celldex currently boasts a Zacks Rank of #3 (Hold).#1 Semiconductor Stock to Buy (Not NVDA)The incredible demand for data is fueling the market's next digital gold rush. As data centers continue to be built and constantly upgraded, the companies that provide the hardware for these behemoths will become the NVIDIAs of tomorrow.One under-the-radar chipmaker is uniquely positioned to take advantage of the next growth stage of this market. It specializes in semiconductor products that titans like NVIDIA don't build. It's just beginning to enter the spotlight, which is exactly where you want to be.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report scPharmaceuticals, Inc. (SCPH): Free Stock Analysis Report Celldex Therapeutics, Inc. (CLDX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks